Articles

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Hematology Unit, Azienda Ospedaliera “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy
Hematology Unit, Azienda Ospedaliera “Spedali Civili”, Brescia, Italy
Chair of Hematology, University of Catania, Italy
U.O. Ematologia I, IRCCS AOU S. Martino-IST, Genova, Italy
Hematology Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Ospedaliero-Universitaria di Udine, Italy
Hematology and Bone Marrow Transplantation Unit, Department of Hematology and Oncology, “G. da Saliceto” Hospital, Piacenza, Italy
Hematology and Stem Cell Transplantation Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord (AORMN), Pesaro, Italy
Clinical Hematology Unit, IRCCS AOU S. Martino-IST, Genova, Italy
Hematology Unit, “Santa Maria delle Croci” Hospital, Ravenna, Italy
Hematology Unit, “Pugliese-Ciaccio” Hospital, Catanzaro, Italy
Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy
Hematology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Foggia, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Italy
Chair of Hematology, Department of Biochemistry and Medical Biotechnologies, “Federico II” University, Napoli, Italy
Chair of Hematology, Department of Clinical and Biological Sciences, “S. Luigi Gonzaga” University Hospital, University of Torino, Orbassano (TO), Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Italy
Department of Hematology and Oncology “L. and A. Seràgnoli”, University of Bologna, Italy
Vol. 101 No. 10 (2016): October, 2016 https://doi.org/10.3324/haematol.2016.144949